Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Bought by Vestal Point Capital LP

Vestal Point Capital LP raised its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 151.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,230,000 shares of the company’s stock after purchasing an additional 740,000 shares during the quarter. Vestal Point Capital LP’s holdings in Voyager Therapeutics were worth $6,974,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Rhumbline Advisers lifted its holdings in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after acquiring an additional 2,354 shares in the last quarter. Empowered Funds LLC boosted its position in Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock worth $268,000 after purchasing an additional 2,397 shares during the period. Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock worth $378,000 after purchasing an additional 2,400 shares during the period. Picton Mahoney Asset Management boosted its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Upgrades and Downgrades

VYGR has been the subject of a number of research reports. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group decreased their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.39.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $3.30 on Monday. Voyager Therapeutics, Inc. has a 12 month low of $2.75 and a 12 month high of $9.55. The firm has a market capitalization of $182.61 million, a P/E ratio of 4.65 and a beta of 0.95. The company’s fifty day moving average price is $3.43 and its two-hundred day moving average price is $4.78.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. On average, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity

In other news, CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.39% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.